Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2656 to 2670 of 8928 results

  1. Heart failure - sacubitril valsartan [ID822]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  2. Ertugliflozin in a triple therapy regimen for treating type 2 diabetes [ID1160]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  3. Empagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  4. Ertugliflozin as monotherapy and in dual therapy for treating type 2 diabetes [ID1158]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  5. Dapagliflozin in triple therapy regimens for treating type 2 diabetes [ID962]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  6. Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy) [ID756]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  7. Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  8. Canagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  9. Dapagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  10. Pulmonary sarcoidosis: infliximab (ES2)

    Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

    Evidence summary
    Published
    20 December 2016

  11. Antimicrobial prescribing: meropenem with vaborbactam (ES21)

    Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making

    Evidence summary
    Published
    20 November 2019

  12. Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)

    Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated

    Evidence summary
    Published
    18 December 2019

  13. Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis

    Evidence summary
    Published
    21 July 2020

  14. Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)

    Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam

    Evidence summary
    Published
    28 October 2020

  15. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin

    Evidence summary
    Published
    5 January 2021